Cristin Hubbard is the Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical Inc., a leading biotechnology company focused on developing and commercializing innovative therapies for rare diseases. Hubbard joined BioMarin in 2018 and has since played a pivotal role in steering the company's commercial strategy and operations. With a robust background in the pharmaceutical industry, she brings over two decades of experience in global commercial leadership, product launches, and strategic planning. Before joining BioMarin, Hubbard held several key positions that shaped her expertise in the biotech sector. She was the Senior Vice President and Chief Commercial Officer at Relypsa, where she led the successful launch of Veltassa, a treatment for hyperkalemia. Prior to Relypsa, she spent over 15 years at Amgen, where she held various roles of increasing responsibility, including General Manager for Amgen Canada and Vice President of Sales and Marketing for Amgen's nephrology and oncology portfolios. Her strategic vision and leadership were instrumental in driving significant growth and market penetration for Amgen's products. In her current role at BioMarin, Hubbard oversees the company's global commercial operations, including marketing, sales, and market access. She is responsible for the commercialization of BioMarin's portfolio of therapies, which includes treatments for diseases such as hemophilia, achondroplasia, and phenylketonuria. Under her leadership, BioMarin has successfully launched several groundbreaking therapies, significantly enhancing patient access to life-changing treatments. Hubbard's dedication to improving the lives of patients with rare diseases, combined with her strategic acumen, continues to drive BioMarin's success and growth in the competitive biotechnology landscape.